Dialysis With CARPEDIEM®: French Multicentric Experience in 25 Patients
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 25
- Locations
- 1
- Primary Endpoint
- Serum potassium
Study Overview
Brief Summary
Historically, CKRT and hemodialysis were performed in small infants and newborns with devices developed for adults with high rates of complications and mortality.
We aim to retrospectively report the first multicenter French experience of CARPEDIEM® use and evaluate the efficacy, feasibility, outcomes, and technical considerations of this new device in a population of neonates and small infant. Compared to adult's device continuous renal replacement therapy with an adapted machine allowed successful blood purification without severe complications even in low birth weight neonates.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 0 Years to 3 Years (Child)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Renal replacement therapy with another device than Carpediem machine
Outcomes
Primary Outcomes
Serum potassium
Time Frame: 3 years
Survival
Time Frame: 3 years
Serum creatinine
Time Frame: 3 years
Blood urea nitrogen
Time Frame: 3 years
Ammonia levels
Time Frame: 3 years
Secondary Outcomes
- Ultrafiltration flow(3 years)
- Time of treatments(3 years)
- Number of sessions(3 years)
- Vascular access(3 years)
- Priming circuit(3 years)
- Blood flow(3 years)
- Anticoagulation(3 years)
- Size of the circuit(3 years)
- Death(3 years)
- CKRT modality(3 years)
- Clotting circuit and other dysfunction circuit(3 years)